menu

Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Practical Guidance for the Community Oncologist — Incorporating Advances in Therapy for Metastatic TNBC: A Focus on TROP2

1.00 credits
60 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC.

    What are the latest data with these ADCs? Why is TROP2 an effective target in TNBC? How do we best incorporate these TROP2-targeted ADCs into TNBC care? This expert-led recording from a series of national visiting lecture series updates clinicians on how recently approved and investigational ADCs overcome current challenges in TNBC treatment. This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations. The activity includes excerpts from the live question and answer session as well as downloadable resources to improve care for your patients with TNBC.

  • Disclosure of Conflicts of Interest

    As a provider of continuing education, Rush University Medical Center asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months.  There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies.  Individuals must disclose regardless of their view of the relevance of the relationship to the education.  Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

    Disclosure Statement (potential conflict to disclose): 

    Sara Hurvitz, MD, FACP (Faculty) discloses that she has Contracted Research Paid to Institution: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, CytomX, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, Inc., GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Phoenix Molecular Designs, Pieris Pharmaceuticals, Puma Biotechnology, Inc., Radius Health, Sanofi, Seattle Genetics/Seagen, and Zymeworks.
    Preclinical work (grant paid to UCLA): Ambrx, Samumed, National/International PI: Novartis, Daiichi Sankyo, Genentech/Roche, and Seagen.
    Steering Committee: Daiichi Sankyo/AstraZeneca, Genentech/Roche, Lilly, Novartis, and Sanofi.
    Travel Expenses: Lilly (2019).
    Uncompensated Consulting/Ad Boards: 4D Pharma, Ambrx, Amgen, Artios, Arvinas, Biotheranostics, Daiichi Sankyo, Dantari, Genentech/Roche, Immunomedics, Lilly, MacroGenics, Novartis, NKMax, Pieris Pharmaceuticals, Pyxis, and Seagen.

    Staff Disclosure
    ACHL and Rush University Medical Center staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

    Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

  • Target Audience

    This activity is intended for oncologists/hematologists, oncology nurses and the multidisciplinary healthcare team who are involved in the care of patients with triple negative breast cancer.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Discuss new and emerging targeted treatment approaches in the setting of TNBC
    • Discuss the role of ADC therapies and TROP2 for TNBC
    • Implement strategies to facilitate the use of novel and emerging therapies for TNBC in community-based settings
  • Accreditation and Credit Designation Statements

    In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity is being presented without bias and with commercial support.

    Rush University Medical Center designates this internet enduring material for a maximum of (1) AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Rush University Medical Center designates this internet enduring material for a maximum of (1) nursing contact hour.

  • Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    Supported by an educational grant from Gilead Sciences, Inc.

  • Method of Participation

    This activity will take approximately 60-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    For questions, contact Michelle Forcier at mforcier@achlcme.org.   

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Are you involved in treating patients with triple negative breast cancer (TNBC)? The emergence of TROP2-directed antibody drug conjugate (ADC) technology has paved the way for exciting new targeted treatment approaches for patients with TNBC.

    What are the latest data with these ADCs? Why is TROP2 an effective target in TNBC? How do we best incorporate these TROP2-targeted ADCs into TNBC care? This expert-led recording from a series of national visiting lecture series updates clinicians on how recently approved and investigational ADCs overcome current challenges in TNBC treatment. This activity also reviews patient cases that incorporate the latest clinical evidence and recommendations. The activity includes excerpts from the live question and answer session as well as downloadable resources to improve care for your patients with TNBC.

  • Disclosure of Conflicts of Interest

    As a provider of continuing education, Rush University Medical Center asks everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months.  There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies.  Individuals must disclose regardless of their view of the relevance of the relationship to the education.  Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.

    Disclosure Statement (potential conflict to disclose): 

    Sara Hurvitz, MD, FACP (Faculty) discloses that she has Contracted Research Paid to Institution: Ambrx, Amgen, AstraZeneca, Arvinas, Bayer, CytomX, Daiichi Sankyo, Dignitana, Genentech/Roche, Gilead Sciences, Inc., GlaxoSmithKline, Immunomedics, Lilly, MacroGenics, Novartis, Pfizer, OBI Pharma, Phoenix Molecular Designs, Pieris Pharmaceuticals, Puma Biotechnology, Inc., Radius Health, Sanofi, Seattle Genetics/Seagen, and Zymeworks.
    Preclinical work (grant paid to UCLA): Ambrx, Samumed, National/International PI: Novartis, Daiichi Sankyo, Genentech/Roche, and Seagen.
    Steering Committee: Daiichi Sankyo/AstraZeneca, Genentech/Roche, Lilly, Novartis, and Sanofi.
    Travel Expenses: Lilly (2019).
    Uncompensated Consulting/Ad Boards: 4D Pharma, Ambrx, Amgen, Artios, Arvinas, Biotheranostics, Daiichi Sankyo, Dantari, Genentech/Roche, Immunomedics, Lilly, MacroGenics, Novartis, NKMax, Pieris Pharmaceuticals, Pyxis, and Seagen.

    Staff Disclosure
    ACHL and Rush University Medical Center staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

    Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.

  • Target Audience

    This activity is intended for oncologists/hematologists, oncology nurses and the multidisciplinary healthcare team who are involved in the care of patients with triple negative breast cancer.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Discuss new and emerging targeted treatment approaches in the setting of TNBC
    • Discuss the role of ADC therapies and TROP2 for TNBC
    • Implement strategies to facilitate the use of novel and emerging therapies for TNBC in community-based settings
  • Accreditation and Credit Designation Statements

    In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    This activity is being presented without bias and with commercial support.

    Rush University Medical Center designates this internet enduring material for a maximum of (1) AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

    Rush University Medical Center designates this internet enduring material for a maximum of (1) nursing contact hour.

  • Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

  • Provider(s)/Educational Partner(s)

  • Commercial Support

    Supported by an educational grant from Gilead Sciences, Inc.

  • Method of Participation

    This activity will take approximately 60-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

    For questions, contact Michelle Forcier at mforcier@achlcme.org.   

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule30 Nov 2022